MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13075-025-03622-8

Медицинская библиотека · Arthritis research & therapy · 2025

Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort.

Kandane-Rathnayake Rangi, Louthrenoo Worawit, Lau C S, Hamijoyo Laniyati, Cho Jiacai, Lateef Aisha, Luo Shue Fen, Wu Yeong-Jian, Navarra Sandra, Zamora Leonid, Li Zhanguo, Chen Yi-Hsing, Oon Shereen, Chan Madelynn, Sockalingam Sargunan, Hao Yanjie, Zhang Zhuoli, Bae Sang-Cheol, Kikuchi Jun, Takeuchi Tsutomu, Katsumata Yasuhiro, Basnayake Bmdb, Goldblatt Fiona, O'Neill Sean, Pek Ling Ng Kristine, Tugnet Nicola, Sapsford Mark, Poh Yih Jia, Tee Cherica, Tee Michael, Ohkubo Naoaki, Lefeber Adrienne O'Donnell, Shisha Tamas, Tanaka Yoshiya, Golder Vera, Nikpour Mandana, Hoi Alberta, Gergely Peter, Morand Eric

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Emerging therapies have the potential to be used in patients with severe refractory systemic lupus erythematosus (srSLE), but no agreed definition of srSLE exists. We evaluated a pilot srSLE definition to assess whether a set of disease activity and treatment thresholds could identify patients with poor outcomes.

METHODS

Data from a 13-country longitudinal SLE cohort, collected prospectively between 2013 and 2020 were analysed. srSLE was defined if a patient was in high disease activity (SLEDAI-2K ≥ 10) despite combination use of at least glucocorticoids (GC) and immunosuppressants (IS) at both the index and preceding visit. Synchronised to the index srSLE visit, we assessed disease activity, medication use and treat-to-target (T2T) endpoint attainment over 12 months (m).

RESULTS

Of 3,744 patients studied, 578 (14%) had srSLE, in 1,810 visits. The median [IQR] SLEDAI-2K at the srSLE index visit was 12 [10, 14], which decreased to 6 [4, 10] at 6m and 12m. Most patients remained on combination anti-malarial, GC, and IS at all follow-up time points. The median [IQR] GC dose at the index visit was 10 [5, 20] mg/day; this reduced to 8 mg [5.0, 12.9] at 6m and 5 mg [5.0, 10.0] at 12m. Less than a quarter of patients attained LLDAS and only 1% attained GC-free remission over 12 months.

CONCLUSIONS

A draft definition of srSLE was clearly associated with poor outcomes. Work to evaluate multiple thresholds with which to define srSLE, and their outcomes, is warranted.

Для цитирования: Kandane-Rathnayake Rangi, Louthrenoo Worawit, Lau C S, Hamijoyo Laniyati, Cho Jiacai, Lateef Aisha, Luo Shue Fen, Wu Yeong-Jian, Navarra Sandra, Zamora Leonid, Li Zhanguo, Chen Yi-Hsing, Oon Shereen, Chan Madelynn, Sockalingam Sargunan, Hao Yanjie, Zhang Zhuoli, Bae Sang-Cheol, Kikuchi Jun, Takeuchi Tsutomu, Katsumata Yasuhiro, Basnayake Bmdb, Goldblatt Fiona, O'Neill Sean, Pek Ling Ng Kristine, Tugnet Nicola, Sapsford Mark, Poh Yih Jia, Tee Cherica, Tee Michael, Ohkubo Naoaki, Lefeber Adrienne O'Donnell, Shisha Tamas, Tanaka Yoshiya, Golder Vera, Nikpour Mandana, Hoi Alberta, Gergely Peter, Morand Eric. Prevalence and outcomes of a pilot definition of severe refractory systemic lupus erythematosus: observations from a multinational Asia-Pacific cohort.. Arthritis research & therapy. 2025. DOI: 10.1186/s13075-025-03622-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.